Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (214)	3/16/1998 10:06:00 AM
From: Candle stick	Read Replies (1) \| Respond to of 656

I heard that Immunex is in talks with a company, Cytoclonal pharmacuetics (CYPH)....they have valuable patents for a production method of Paclitaxol (Taxol), and some other drugs....supposedly, this method of production is 10 times cheaper than the current production method currently used by Bristol Meyers. Taxol, used in breast cancer treatment, is a multi billion dollar market, and the patent protection for Bristol Meyers expired in Dec. 1997...... CYPH is a small company with no cash, but very valuable patents...in the hands of Immunex, these patents could be very valuable...anyone have any info about these talks? thanks in advance.........;^)